

प्रो.(डॉ.) अतुल गोयल

Prof. (Dr.) Atul Goel

MD (Med.)

स्वास्थ्य सेवा महानिदेशक

DIRECTOR GENERAL OF HEALTH SERVICES



भारत सरकार  
स्वास्थ्य एवं परिवार कल्याण मंत्रालय  
स्वास्थ्य सेवा महानिदेशालय

Government of India  
Ministry of Health & Family Welfare  
Directorate General of Health Services

No. Z-14020/80/2023-Lep.(E-8242437)

06<sup>th</sup> March 2025

Sub: Revised treatment regimen for Pauci-Bacillary (PB) and Multi-Bacillary (MB) cases in India- reg.

*Dear Colleagues,*

This is with reference to DO Letter No. Z-14020/80/2023-Lep dated 17 January 2024 regarding 'Revised classification of leprosy and treatment regimen for Pauci- Bacillary (PB) and Multi-bacillary (MB) cases in India and supply of Anti-Leprosy Drugs according to the revised treatment regimen'.

National Leprosy Eradication Program (NLEP) is taking all required steps to stop the transmission of Leprosy at the Sub-national level by 2027. Following which, The Ministry of Health & Family Welfare, GOI introduced a 3-drug regimen for Pauci-Bacillary (PB) cases in place of a 2-drug regimen for 6 months, via aforementioned D.O letter.

Revised classification of leprosy and treatment regimen for PB and MB cases in India as adopted by MoHFW, GoI is enclosed (**Annexure-1**) and shall be implemented in all States/UTs from **1<sup>st</sup> April 2025**.

However, it should be noted that for PB patients on treatment as of 31st March 2025 shall continue with the older MDT regimen of 2 drugs until released from treatment (RFT) and for MB patients on treatment as of 31st March 2025 shall continue with the MB MDT regimen.

We believe that this new treatment regimen for leprosy patients will mark a significant step forward in our collective efforts to eradicate leprosy in India by 2027.

"Ending Stigma, Embracing Dignity"

*Warm Regards,*

  
(Atul Goel)

To

1. Directors of All AIIMS.
2. Dean of All Govt. Hospitals.
3. Dean of All Medical Colleges.
4. DGAFMS for circulation to all Defense Services Commandant of Army Hospital (R & R).
5. Director General of Railway Health Services.
6. Directors of All leprosy institutes (CLTRI/RLTRI).
7. State Leprosy Officers (SLO's) of All States/UTs.
8. Country Coordinator, ILEP India.

Copy to :

PPS to EA (Leprosy), MoHFW, GoI.

### **Annexure-1**

#### **A) Revised Classification of Leprosy in India:**

Any one or more of the cardinal sign and/or laboratory test result as mentioned below:

S. No.	Type	Skin lesions	Nerve (s) Involvement	Bacilli in laboratory-based test (Slit Skin Smear)
1	Pauci-Bacillary (PB)	1-5	No nerve (0)	Absent (Negative)
2	Multi-Bacillary (MB)	More than 5 (>5)	One or more nerve involved ( $\geq 1$ )	Present (Positive)

#### **B) Revised Treatment Regimen of Leprosy in India:**

S. No.	Types		Duration of treatment	Dapsone	Clofazimine	Rifampicin
1	Pauci-Bacillary (PB)	Adult	6 months	100 mg Daily	300 mg once a month & 50 mg daily	600 mg once a month
		Child (9-14 years)	6 months	50 mg Daily	150 mg once a month & 50 mg alternate day	450 mg once a month
2	Multi-Bacillary (MB)	Adult	12 months	100 mg Daily	300 mg once a month & 50 mg daily	600 mg once a month
		Child (9-14 years)	12 months	50 mg Daily	150 mg once a month & 50 mg alternate day	450 mg once a month